Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4

被引：6

作者：

Marascio, Nadia ^{[1
]}

Mazzitelli, Maria ^{[2
]}

Pavia, Grazia ^{[1
]}

Giancotti, Aida ^{[1
]}

Barreca, Giorgio Settimo ^{[1
]}

Costa, Chiara ^{[2
]}

Pisani, Vincenzo ^{[2
]}

Greco, Giuseppe ^{[2
]}

Serapide, Francesca ^{[2
]}

Trecarichi, Enrico Maria ^{[2
]}

Casalinuovo, Francesco ^{[3
]}

Liberto, Maria Carla ^{[1
]}

Matera, Giovanni ^{[1
]}

Torti, Carlo ^{[2
]}

机构：

[1] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Unit Clin Microbiol, I-88100 Catanzaro, Italy

[2] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Unit Infect & Trop Dis, I-88100 Catanzaro, Italy

[3] Inst Expt Vet Med Southern Italy, I-88100 Catanzaro, Italy

来源：

CELLS | 2019年 / 8卷 / 05期

关键词：

pediatric patients; Hepatitis C virus 4; sofosbuvir; ledipasvir; RESISTANCE-ASSOCIATED SUBSTITUTIONS; TRANSMISSION; SOFOSBUVIR;

D O I：

10.3390/cells8050416

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Direct-acting antiviral drugs to cure infections with Hepatitis C virus (HCV) achieve a sustained virological response (SVR) in more than 90% of adult patients. At present, clinical trials are ongoing and real-life data are still limited in children. Herein, we report two cases of pediatric patients treated with fixed-dose combination of sofosbuvir/ledipasvir, already approved to treat HCV4 genotype. Both young girls achieved SVR even though HCV4 isolates carried L28M and M31L NS5A resistance-associated substitutions (RASs). Therefore, possible effects of these RASs merit further study, especially in children.

引用

页数：9

共 50 条

[21] Sofosbuvir/Ledipasvir Fixed Dose Combination Is Safe and Effective in HCV Infected Populations Including Decompensated Patients and Patients With Prior Sofosbuvir Treatment Experience
Gane, Edward
Hyland, Rob H.
Pang, Phil
Symonds, William T.
McHutchison, John G.
Stedman, Catherine A.
[J]. GASTROENTEROLOGY, 2014, 146 (05) : S904 - S905
[22] Ledipasvir/sofosbuvir for 6 weeks in HIV-infected patients with acute HCV infection
Nelson, M.
Bhagani, S.
Hyland, R.
Yun, C.
Natha, M.
Zheng, W.
Brainard, D.
McHutchinson, J.
Jackson, A.
Ingiliz, P.
Lutz, T.
Rockstroh, J.
[J]. HIV MEDICINE, 2016, 17 : 7 - 7
[23] Diabetes Mellitus in HIV/HCV Co-Infected Patients Treated with Ledipasvir and Sofosbuvir
Bhatti, Zabeer
Gill, Dalvir
Virk, Jaswinder
Sivalingam, Devamohan
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S1360 - S1360
[24] High Rates of SVR in Patients with Genotype 1 HCV Infection and Cirrhosis After Treatment with Ledipasvir/Sofosbuvir plus Ribavirin or Ledipasvir/Sofosbuvir+GS-9669 for 8 weeks
Lawitz, Eric
Poordad, Fred
Hyland, Robert H.
Wang, Jing
Pang, Phillip S.
Symonds, William T.
McHutchison, John G.
Membreno, Fernando E.
[J]. HEPATOLOGY, 2014, 60 : 1143A - 1143A
[25] Resistance Analysis of Treatment-Experienced HCV Genotype 1 Infected Patients Retreated with Sofosbuvir
Mo, Hongmei
Doehle, Brian
Gontcharova, Viktoria
Chodavarapu, Ramakrishna K.
Kanwar, Bittoo
Jacobson, Ira M.
Pol, Stanislas
Brainard, Diana M.
McHutchison, John G.
Miller, Michael D.
[J]. HEPATOLOGY, 2014, 60 : 664A - 664A
[26] 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)
Boerekamps, Anne
Vanwolleghem, Thomas
van der Valk, Marc
van den Berk, Guido E.
van Kasteren, Marjo
Posthouwer, Dirk
Dofferhoff, Anthonius S. M.
van Hoek, Bart
Ramsoekh, Dewkoemar
Koopsen, Jelle
Schinkel, Janke
Florence, Eric
Arends, Joop E.
Rijnders, Bart J.
[J]. JOURNAL OF HEPATOLOGY, 2019, 70 (03) : 554 - 557
[27] Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase II studies
Lawitz, Eric
Poordad, Fred
Hyland, Robert H.
Wang, Jing
Liu, Lin
Dvory-Sobol, Hadas
Brainard, Diana M.
McHutchison, John G.
Gutierrez, Julio A.
[J]. ANTIVIRAL THERAPY, 2016, 21 (08) : 679 - 687
[28] Sustained virological response to treatment in 100% of patients recently infected, nosocomially, with HCV genotype 2
Sikuler, E
Kaspa, RT
Shemer-Avni, Y
Delgado, J
Zilberman, D
Fich, A
Baruch, Y
Hyam, E
[J]. HEPATOLOGY, 2005, 42 (04) : 678A - 679A
[29] Decline in eGFR in HCV-infected patients while on treatment with sofosbuvir/ledipasvir or PrOD regimens is not dependent on baseline eGFR
Alkadi, M.
Ren, Y.
Abou-Samra, A-B
Puenpatom, A.
Arduino, J. M.
Kumar, R.
Butt, A. A.
[J]. JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S724 - S724
[30] SUSTAINED VIROLOGICAL RESPONSE IN HCV INFECTED DECOMPENSATED CIRRHOTIC PATIENTS TREATED WITH DACLATASVIR AND SOFOSBUVIR
Tun, Kyaw Thet
Win, Nang K. T.
Kyaw, A. Mi Mi
Lin, Sithu
Maung, Moe Zaw
Myint, Khin Thuzar
Hlaing, Naomi Khaing Than
[J]. HEPATOLOGY, 2019, 70 : 967A - 967A

← 1 2 3 4 5 →